Tuesday - May 13, 2025

LOGIN  |  REGISTER
Assertio

BrightSpring Health Services to Announce First Quarter 2025 Financial Results on May 2, 2025

April 10, 2025 | Last Trade: US$23.49 1.14 5.10

LOUISVILLE, Ky., April 10, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its first quarter 2025 financial results on Friday, May 2, 2025, prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.

To participate in the conference call, please register here before the 8:30 a.m. ET start. A live and archived webcast of the call will be available on the Company’s investor relations website at https://ir.brightspringhealth.com under the “Events & Presentations” section, where related presentation materials will be posted prior to the conference call. The webcast may be accessed directly here.

About BrightSpring Health Services

BrightSpring Health Services provides complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 450,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and often industry-leading quality metrics across its services lines while improving the quality of life and health for high-need individuals and reducing overall costs to the healthcare system.

Contact

Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
ir@brightspringhealth.com 

Media Contact:
Leigh White
leigh.white@brightspringhealth.com 
502.630.7412

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page